Dashboard
Manage Tickers

CRSPCRISPR Therapeutics AG

Nasdaq crisprtx.com


$ 54.00 $ -1.37 (-2.47 %)    

Friday, 28-Jun-2024 15:59:49 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 54.01
$ 55.52
$ 0.00 x 0
$ 0.00 x 0
$ 53.37 - $ 55.56
$ 37.55 - $ 91.10
1,313,469
na
4.42B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-15-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 04-27-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-27-2020 06-30-2020 10-Q
17 04-28-2020 03-31-2020 10-Q
18 02-12-2020 12-31-2019 10-K
19 10-28-2019 09-30-2019 10-Q
20 07-29-2019 06-30-2019 10-Q
21 04-29-2019 03-31-2019 10-Q
22 02-25-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-08-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-10-2017 12-31-2016 10-K
31 11-22-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

guggenheim-assumes-crispr-therapeutics-at-neutral
Guggenheim Assumes CRISPR Therapeutics at ...
06/28/2024 11:56:49

Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating.

needham-reiterates-buy-on-crispr-therapeutics-maintains-88-price-target
Needham Reiterates Buy on CRISPR Therapeut...
06/27/2024 09:35:14

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.

Core News & Articles
Intellia Therapeutics Presents Data On Red...
06/25/2024 19:32:54

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 ...

piper-sandler-reiterates-overweight-on-crispr-therapeutics-maintains-105-price-target
Piper Sandler Reiterates Overweight on CRI...
06/17/2024 17:13:14

Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and maintains $105 pric...

needham-reiterates-buy-on-crispr-therapeutics-maintains-88-price-target
Needham Reiterates Buy on CRISPR Therapeut...
06/17/2024 09:36:07

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.

citigroup-maintains-buy-on-crispr-therapeutics-lowers-price-target-to-84
Citigroup Maintains Buy on CRISPR Therapeu...
05/23/2024 17:27:52

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from ...

crispr-therapeutics-julianne-bruno-mba-promoted-to-coo-effective-may-23-2024
CRISPR Therapeutics' Julianne Bruno, M.B.A...
05/23/2024 12:17:01

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer-ZUG, Swi...

oppenheimer-maintains-outperform-on-crispr-therapeutics-lowers-price-target-to-95
Oppenheimer Maintains Outperform on CRISPR...
05/10/2024 16:47:42

Oppenheimer analyst Jay Olson maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from...

jmp-securities-reiterates-market-outperform-on-crispr-therapeutics-maintains-86-price-target
JMP Securities Reiterates Market Outperfor...
05/09/2024 18:24:32

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $...

wells-fargo-maintains-equal-weight-on-crispr-therapeutics-lowers-price-target-to-65
Wells Fargo Maintains Equal-Weight on CRIS...
05/09/2024 16:04:05

Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target fr...

cantor-fitzgerald-reiterates-neutral-on-crispr-therapeutics
Cantor Fitzgerald Reiterates Neutral on CR...
05/09/2024 15:02:26

Cantor Fitzgerald analyst Eric Schmidt reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral.

barclays-maintains-equal-weight-on-crispr-therapeutics-lowers-price-target-to-67
Barclays Maintains Equal-Weight on CRISPR ...
05/09/2024 14:50:23

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from ...

needham-maintains-buy-on-crispr-therapeutics-lowers-price-target-to-88
Needham Maintains Buy on CRISPR Therapeuti...
05/09/2024 13:40:36

Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $90 to $88.

baird-maintains-neutral-on-crispr-therapeutics-raises-price-target-to-52
Baird Maintains Neutral on CRISPR Therapeu...
05/09/2024 10:41:48

Baird analyst Jack Allen maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and raises the price target from $46 to...

crispr-therapeutics-q1-eps-143-misses-142-estimate-sales-50400k-miss-2811m-estimate
CRISPR Therapeutics Q1 EPS $(1.43) Misses ...
05/08/2024 21:01:20

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of...

citigroup-maintains-buy-on-crispr-therapeutics-raises-price-target-to-89
Citigroup Maintains Buy on CRISPR Therapeu...
04/18/2024 16:12:47

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from ...

needham-reiterates-buy-on-crispr-therapeutics-maintains-90-price-target
Needham Reiterates Buy on CRISPR Therapeut...
04/11/2024 10:38:49

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $90 price target.

if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-2000-today
If You Invested $1000 In This Stock 5 Year...
03/19/2024 15:31:42

cathie-woods-ark-invest-keeps-dumping-coinbase-shares-amid-bitcoin-crypto-buzz
Cathie Wood's Ark Invest Keeps Dumping Coi...
03/13/2024 03:57:30

On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global ...

mizuho-maintains-buy-on-crispr-therapeutics-raises-price-target-to-99
Mizuho Maintains Buy on CRISPR Therapeutic...
03/06/2024 13:09:44

Mizuho analyst Salim Syed maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $99.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)